Physician profile
Jonathan Hsu
NPI 1649726514
$23,567.58
in general payments reported to CMS, 2019-2025
26 companies · $2,610 in 2025
The $2,610 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $694 · 2022: $739 · 2023: $731 · 2024: $19K · 2025: $2,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $4,723 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,223.01 |
| Food and Beverage | $4,722.63 |
| Education | $188.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17,223.01 | 2024 | Tacticath Ablation Catheter, Sensor Enabled, Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $1,270.67 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $1,049.49 | 2022-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $943.79 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.06 | 2021-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $300.07 | 2023-2025 | Prolastin-C Liquid |
| Amgen INC. | $275.42 | 2024-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $273.65 | 2023-2025 | Dupixent |
| Harmony Biosciences LLC | $263.71 | 2021 | |
| Verona Pharma, INC. | $261.38 | 2025 | Ohtuvayre |
| Genzyme Corporation | $245.66 | 2024-2025 | |
| Alk-Abello, INC | $142.44 | 2024-2025 | Odactra, Ragwitek, Grastek |
| Takeda Pharmaceuticals U.S.A., INC. | $129.39 | 2022-2024 | Glassia |
| Novo Nordisk INC | $124.55 | 2022 | |
| Fisher & Paykel Healthcare INC | $104.37 | 2024-2025 | Fisher & Paykel Healthcare |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $91.73 | 2024-2025 | Arikayce, Brinsupri |
| Pulmonx Corporation | $81.10 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $46.56 | 2024-2025 | Lumryz |
| Mylan Specialty L.P. | $42.84 | 2024 | Yupelri |
| 3b Medical, INC. | $40.65 | 2025 | Luna |
| Axsome Therapeutics, INC. | $38.07 | 2023-2024 | Sunosi |
| Boston Scientific Corporation | $18.48 | 2023 | |
| Lilly USA, LLC | $17.85 | 2025 | Zepbound |
| United Therapeutics Corporation | $16.93 | 2025 | Tyvaso |
| Inspire Medical Systems, INC. | $15.72 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.